论文部分内容阅读
1993年以来我院将甲胎蛋白（AFP）、癌胚抗原（CEA）、人血清铁蛋白（SF）、β_2-微球蛋白（β_2-m）联合检测应用于临床。本文对44例肺癌患者此四项检测资料进行了分析,并探讨其价值。 材料和方法 一、临床资料:随机抽取228例肝病患者,其中肝癌44例,急性肝炎42例,慢性肝炎75例,肝硬化57例。肝癌患者44例（男28,女16）,年龄19～88岁,均为我院住院患者,诊断经CT或手术证实。 二、方法:AFP、CEA、SF、β_2-m检测均采用放射免疫分析法。AFP、CER试剂盒由潍坊3V公司提供。SF试剂盒由上海放射免疫分析技术研究所供给。β_2-m试剂盒为北方生物技术研究所生产。FJ-2088Pγ-免疫计数仪为西安262厂生产。正常值（ng/ml）,AFP< 25;SF男:19.0～295.0,女:5.0～142.0;β_2-m1700～3300。 结果 一、肝癌患者血清AFP含量:<25,7例、～400,8例、～800,3例、～1600,6例、>1600,20例。阳性率84.1％。含量<400的仅占阳性人数的21.6％。 二、肝癌患者血清CEA含量:AFP阳性肝癌37例,其CEA范围9.6～18.O;AFP阴性肝癌7例其CEA范围7.5～14.7。以上两种情况CEA无显著差异（p>0.05）。阳性率9％。 三、肝癌患者SF检测:37例AFP阳性肝癌其SF阳性22例,占59.5％;7例AFP阴性肝癌其SF阳性6
Since 1993, the joint detection of AFP, CEA, human serum ferritin (SF) and β 2 -microglobulin (β 2 -m) has been used clinically in our hospital. This paper analyzes the four test data of 44 patients with lung cancer and discusses its value. Materials and Methods First, clinical data: 228 patients with liver disease were randomly selected, including 44 cases of liver cancer, 42 cases of acute hepatitis, 75 cases of chronic hepatitis, and 57 cases of liver cirrhosis. 44 patients with liver cancer (male 28, female 16), aged 19 to 88 years old, were hospitalized patients in our hospital, the diagnosis confirmed by CT or surgery. Second, methods: AFP, CEA, SF, β_2-m detection radioimmunoassay. The AFP and CER kits are provided by Weifang 3V. The SF kit is supplied by the Shanghai Institute of Radioimmunoassay. The β_2-m kit was produced by the Northern Institute of Biotechnology. The FJ-2088P gamma-immune counter was produced at Xi’an 262 Factory. Normal value (ng/ml), AFP<25; SF male: 19.0 to 295.0, female: 5.0 to 142.0; β_2-m1700 to 3300. Results 1. Serum AFP levels in patients with liver cancer: <25, 7 cases, ~ 400, 8 cases, ~ 800, 3 cases, ~ 1600, 6 cases,> 1600, and 20 cases. The positive rate was 84.1%. The content of <400 only accounted for 21.6% of the positive number. Second, liver cancer patients serum CEA content: AFP-positive liver cancer in 37 cases, the CEA range of 9.6 to 18. O; AFP-negative liver cancer in 7 cases of its CEA range of 7.5 to 14.7. There was no significant difference in CEA between the above two cases (p>0.05). The positive rate is 9%. III. Detection of SF in patients with hepatocellular carcinoma: SF positive in 22 cases of AFP-positive liver cancer in 22 cases (59.5%); SF-positive in 7 cases of AFP-negative liver cancer 6